Individualized Radical Radiotherapy of Non-Small-Cell Lung Cancer Based on Normal Tissue Dose Constraints: A Feasibility Study

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 5, 2008, Pages 1394-1401

  van Baardwijk, Angela ^a   Bosmans, Geert ^a   Boersma, Liesbeth ^a   Wanders, Stofferinus ^a   Dekker, André ^a   Dingemans, Anne Marie C ^b   Bootsma, Gerben ^c   Geraedts, Wiel ^c   Pitz, Cordula ^d   Simons, Jean ^e   Lambin, Philippe ^a   De Ruysscher, Dirk ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d LAURENTIUS HOSPITAL   (Netherlands)

^e Sint Jans Gasthuis ^*  (Netherlands)

Author keywords

Mean lung dose; Non small cell lung cancer; Normal tissue constraints; Radiotherapy; Toxicity

Indexed keywords

DECISION MAKING; DRUG PRODUCTS; ELECTROTHERAPEUTICS; PLANNING; RESOURCE ALLOCATION; TERMINOLOGY;

COMMON TERMINOLOGY CRITERIA; CONCURRENT CHEMORADIATION; FEASIBILITY STUDIES; FORCED EXPIRATORY VOLUME IN 1; LOCAL RECURRENCE; LUNG FUNCTIONS; MEAN LUNG DOSE; MEDICALLY INOPERABLE; NON-SMALL CELL LUNG CANCER; NORMAL TISSUE CONSTRAINTS; NORMAL TISSUES; RADICAL RADIOTHERAPY; RADIOTHERAPY; SPINAL CORDS; TOXICITY; WORLD HEALTH ORGANIZATION;

BIOLOGICAL ORGANS;

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COUGHING; DYSPHAGIA; DYSPNEA; FEASIBILITY STUDY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEASIBILITY STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SPINAL CORD; SURVIVAL RATE;

EID: 47149099230     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.11.070     Document Type: Article

References (42)

1. Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83 (1991) 417-423
2. Saunders M., Dische S., Barrett A., et al. Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 52 (1999) 137-148
3. Belderbos J.S., Heemsbergen W.D., De Jaeger K., et al. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 126-134
4. Kong F.M., Ten Haken R.K., Schipper M.J., et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 324-333
5. Perez C.A., Pajak T.F., Rubin P., et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59 (1987) 1874-1881
6. Rowell N.P., and O'Rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev (2004) CD002140
7. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
8. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 46 (2004) 87-98
9. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23 (2005) 5910-5917
10. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
11. Belderbos J., Heemsbergen W., Hoogeman M., et al. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 75 (2005) 157-164
12. Firat S., Byhardt R.W., and Gore E. Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54 (2002) 357-364
13. Martel M.K., Ten Haken R.K., Hazuka M.B., et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 24 (1999) 31-37
14. Kocak Z., Borst G.R., Zeng J., et al. Prospective assessment of dosimetric/physiologic-based models for predicting radiation pneumonitis. Int J Radiat Oncol Biol Phys 67 (2007) 178-186
15. Kwa S.L., Lebesque J.V., Theuws J.C., et al. Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42 (1998) 1-9
16. Wang S., Liao Z., Wei X., et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 66 (2006) 1399-1407
17. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 318-328
18. Kong F.M., Hayman J.A., Griffith K.A., et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65 (2006) 1075-1086
19. De Ruysscher D., Wanders S., Minken A., et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol 77 (2005) 5-10
20. 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: A modeling study. Int J Radiat Oncol Biol Phys 61 (2005) 649-655
21. De Ruysscher D., Wanders S., van Haren E., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: A prospective clinical study. Int J Radiat Oncol Biol Phys 62 (2005) 988-994
22. Fowler J.F., Tome W.A., Fenwick J.D., et al. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 60 (2004) 1241-1256
23. van Baardwijk A., Bosmans G., Bentzen S.M., et al. Radiation dose prescription for non-small cell lung cancer based on normal tissue dose constraints: An in silico trial. Int J Radiat Biol (2007) In press
24. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 (1989) 1748-1756
25. Senan S., De Ruysscher D., Giraud P., et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71 (2004) 139-146
26. ICRU. International Commission on Radiation Units and Measurements Report 50: Prescribing, recording, and reporting photon beam therapy. ICRU: Bethesda, MD; 1993.
27. Nijsten S.M., Mijnheer B.J., Dekker A.L., et al. Routine individualised patient dosimetry using electronic portal imaging devices. Radiother Oncol 83 (2007) 65-75
28. Schultheiss T.E., Kun L.E., Ang K.K., et al. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 31 (1995) 1093-1112
29. Kelsey C.R., Kahn D., Hollis D.R., et al. Radiation-induced narrowing of the tracheobronchial tree: An in-depth analysis. Lung Cancer 52 (2006) 111-116
30. Maguire P.D., Marks L.B., Sibley G.S., et al. 73.6 Gy and beyond: Hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. J Clin Oncol 19 (2001) 705-711
31. Marks L.B., Garst J., Socinski M.A., et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: Report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol 22 (2004) 4329-4340
32. 18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35 (1999) 1773-1782
33. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
34. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21 (2003) 1285-1292
35. van Baardwijk A., Bosmans G., Dekker A., et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol 82 (2007) 145-152
36. Saunders M., Dische S., Barrett A., et al. Continuous Hyperfractionated Accelerated Radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial. CHART Steering Committee. Lancet 350 (1997) 161-165
37. Rodrigues G., Lock M., D'Souza D., et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-A systematic review. Radiother Oncol 71 (2004) 127-138
38. Willner J., Baier K., Caragiani E., et al. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52 (2002) 382-389
39. Rengan R., Rosenzweig K.E., Venkatraman E., et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 60 (2004) 741-747
40. Curran Jr. W.J. Evolving chemoradiation treatment strategies for locally advanced non-small-cell lung cancer. Oncology (Williston Park) 17 (2003) 7-14
41. Groen H.J., van der Leest A.H., Fokkema E., et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: A multicenter phase III study. Ann Oncol 15 (2004) 427-432
42. Huber R.M., Flentje M., Schmidt M., et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 24 (2006) 4397-4404